Sema4, an interdisciplinary health information company led by Eric Schadt, PhD, the Founding Director of the Icahn Institute for Genomics and Multiscale Biology, has acquired rights to some of LifeMap Solution’s assets.
“We are excited to combine LifeMap Solutions’ capabilities with Sema4’s clinical, research and data science expertise as we work toward creating more digital health tools like the successful Asthma Health app,” said Dr Schadt.
“That app launched the largest study of asthma management ever performed and helped patients monitor symptoms and medication usage,” continued Dr Schadt.
Formerly the Mount Sinai Genetic Testing Lab at the Icahn School of Medicine at Mount Sinai, Sema4 aims to revolutionise clinical diagnostics by combining comprehensive screening and diagnostic testing, predictive modelling and open-access data to ultimately transform how diseases are predicted, diagnosed, treated and prevented.
To that end, Sema4 will continue to build new digital platforms to engage patients and empower them to take control of their data. Sema4 will also aggregate and analyse the data to better understand diseases and ensure patients benefit the most from their data.
LifeMap’s various assets and expertise is expected to accelerate Sema4 on its mission.
“This acquisition is a perfect fit,” said LifeMap Solutions founder and CEO, Corey Bridges.
“We are proud of the many partnerships we have forged with industry leaders in relatively short order. The deepest and most significant one, though, has been with Dr Schadt and his team at Mount Sinai. As founder and CEO of Sema4, Dr Schadt has led his team into the commercial realm, where we are finally able to fully integrate our efforts. This represents the culmination of our founding mission,” continued Bridges.
LifeMap was incorporated in May 2014 and in 2015 it became the only commercial developer asked by Apple to participate in the launch of its ResearchKit platform.
LifeMap has worked closely with world-classresearch institutions and commercial organisations such as the Icahn School of Medicine at Mount Sinai, Stanford University School of Medicine, the Mount Sinai – National Jewish Health Respiratory Institute, 23andMe and Medidata.
The company built apps that spanned a wide range of uses, from research-themed Asthma Health and MyHeart Counts, to the chronic-disease managing COPD Navigator, and the patient-services app at Mount Sinai Health System in New York. Numerous research papers based on LifeMap’s technology have been published in peer-reviewed scientific journals such as Nature Biotechnology and JAMA Cardiology.
Terms of the acquisition were not disclosed.